Display options
Cite
Divella R, Daniele A, Abbate I, et al. Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Transl Oncol. 2015;8(4):273-8doi: 10.1016/j.tranon.2015.05.002.
Divella, R., Daniele, A., Abbate, I., Savino, E., Casamassima, P., Sciortino, G., Simone, G., Gadaleta-Caldarola, G., Fazio, V., Gadaleta, C. D., Sabbà, C., & Mazzocca, A. (2015). Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Translational oncology, 8(4), 273-8. https://doi.org/10.1016/j.tranon.2015.05.002
Divella, Rosa, et al. "Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE." Translational oncology vol. 8,4 (2015): 273-8. doi: https://doi.org/10.1016/j.tranon.2015.05.002
Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A. Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Transl Oncol. 2015 Aug;8(4):273-8. doi: 10.1016/j.tranon.2015.05.002. PMID: 26310373; PMCID: PMC4562977.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2015 Aug;8(4):273-8. doi: 10.1016/j.tranon.2015.05.002.

Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Translational oncology

Rosa Divella, Antonella Daniele, Ines Abbate, Eufemia Savino, Porzia Casamassima, Giancarlo Sciortino, Giovanni Simone, Gennaro Gadaleta-Caldarola, Vito Fazio, Cosimo Damiano Gadaleta, Carlo Sabbà, Antonio Mazzocca

Affiliations

  1. Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: [email protected].
  2. Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy.
  3. Department of Pathology, Giovanni Paolo II National Cancer Institute, Bari, Italy.
  4. Hospital "Monsignor Raffaele Dimiccoli", Barletta, Italy.
  5. Unit of Interventional Radiology, Department of Critical Area and Surgery, Giovanni Paolo II National Cancer Institute, Bari, Italy.
  6. Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
  7. Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy; IRCCS "S. de Bellis", National Institute for Digestive Diseases, Bari, Italy. Electronic address: [email protected].

PMID: 26310373 PMCID: PMC4562977 DOI: 10.1016/j.tranon.2015.05.002

Abstract

Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial chemoembolization (TACE). In particular, we show that the guanosine insertion/deletion polymorphism in the promoter region of SERPINE1 gene at the -675 bp position, named 4G/4G, predicts poor prognosis in a cohort of 75 patients with HCC undergoing TACE. By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE. Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE. In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Thromb Haemost. 2008 Feb;99(2):352-6 - PubMed
  2. Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):123-32 - PubMed
  3. Semin Thromb Hemost. 2008 Sep;34(6):562-8 - PubMed
  4. Anticancer Res. 2008 Jan-Feb;28(1A):223-8 - PubMed
  5. Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67 - PubMed
  6. Thromb Haemost. 1999 Apr;81(4):516-21 - PubMed
  7. N Engl J Med. 2000 Jun 15;342(24):1792-801 - PubMed
  8. Circulation. 2003 May 20;107(19):2422-7 - PubMed
  9. Front Biosci (Landmark Ed). 2009 Jan 01;14:1337-61 - PubMed
  10. Thromb Haemost. 1993 Jul 1;70(1):135-7 - PubMed
  11. J Biol Chem. 1993 May 25;268(15):10739-45 - PubMed
  12. Thromb Res. 2012 Oct;130(4):576-85 - PubMed
  13. Blood. 2012 Dec 6;120(24):4873-81 - PubMed
  14. Can J Gastroenterol. 2013 Jun;27(6):351-63 - PubMed
  15. J Cell Sci. 2001 Nov;114(Pt 21):3905-14 - PubMed
  16. Thromb Haemost. 2008 Dec;100(6):1041-6 - PubMed
  17. Cancer Treat Res. 2009;148:43-66 - PubMed
  18. Cancer Res. 2003 Apr 1;63(7):1500-7 - PubMed
  19. Int Surg. 2008 May-Jun;93(3):163-8 - PubMed
  20. Clin Biochem. 2014 Feb;47(3):184-90 - PubMed
  21. Cancer Genomics Proteomics. 2012 Jul-Aug;9(4):193-8 - PubMed
  22. Dig Dis Sci. 2013 Dec;58(12):3389-96 - PubMed
  23. Thromb Res. 2009 Sep;124(4):403-8 - PubMed

Publication Types